Skadden Steers Valeant To $312M Deal For Oral Care Co.

Law360, New York (June 15, 2012, 3:30 PM EDT) -- Canada's Valeant Pharmaceuticals International Inc. has broken into the oral health market with a $312 million deal for a Pennsylvania portfolio company of Water Street Healthcare Partners that specializes in treatments for gum disease, according to an announcement Friday.

OraPharma Inc. boasts the largest specialized pharmaceutical sales team in the dental industry, giving the Canadian drugmaker — whose focus is concentrated in the fields of neurology, dermatology and branded generics — access to a potentially lucrative new market, Valeant said in a statement.

"We are excited...
To view the full article, register now.